AN-1792 (Elan).

摘要: Elan is developing AN-1792 as a potential immunotherapy for Alzheimer's disease (AD). It currently in phase I trials [350904]. Phase II/III trials, running parallel the US and UK, are expected to start by end of 2001 [375061], [383226], [401966]. American Home Products (AHP) collaborating with on research development an directed towards beta-amyloid peptide, including other products [361702]. In September 2000, agreement was established between Elan, AHP Cambridge Antibody Technology (CAT), whereby CAT investigating anti-beta-amyloid human antibodies [394844]. July Merrill Lynch predicted possible late-2001 entry into pivotal NDA filing 2004 [375966]. The clinical program take approximately four years [339630]. April 2001, ABN Amro Hoare Govett stated that, if data from large II trial late satisfied FDA requirements, then might be able file 2003, launch 2005 [407412].